Hagiwara D, Miyake H, Murano K, Morimoto H, Murai M, Fujii T, Nakanishi I, Matsuo M
New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd. Osaka, Japan.
J Med Chem. 1993 Aug 6;36(16):2266-78. doi: 10.1021/jm00068a003.
As an extension of our study on discovering a novel substance P (SP) antagonist, we designed new branched tripeptides containing L-aspartic acid (2 and 5), L-ornithine (3 and 6), and L-lysine (4 and 7) by reconstructing the structure of the previously reported tripeptide SP antagonist [Ac-Thr-D-Trp(CHO)-Phe-NMeBzl (1), FR113680]. The strategy for this design was based on the postulate that the dipeptide half D-Trp(CHO)-Phe-NMeBzl in 1 is essential for receptor recognition. Molecular modeling studies implied that these newly designed tripeptides could mimic the spatial orientations of the essential dipeptide structure. As expected, all of these compounds potently inhibited 3H-SP (1 nM) binding to guinea pig lung membranes in the 10(-8) M range. The 1H-indol-3-ylcarbonyl derivatives (5-7) were slightly more potent than the corresponding 1H-indol-2-ylcarbonyl derivatives (2-4), as predicted by the molecular modeling studies. The structure-activity relationships studies on the selected 1H-indol-3-ylcarbonyl derivatives indicated that the threonine moiety at the side chain can be modified into a variety of structures without any significant loss of the activity. Furthermore in the L-lysine series, even dipeptide compounds having nothing or a simple acyl group at the epsilon-amino group, such as N alpha-[N alpha-(1H-indol-3-ylcarbonyl)-L-lysyl]-N-methyl-N-(phenylmethyl)- L-phenylalaninamide (18b), exhibited potent activity. These dipeptides belong to a new structural class of SP antagonist.
作为我们发现新型P物质(SP)拮抗剂研究的拓展,我们通过重构先前报道的三肽SP拮抗剂[Ac-Thr-D-Trp(CHO)-Phe-NMeBzl (1),FR113680]的结构,设计了含有L-天冬氨酸(2和5)、L-鸟氨酸(3和6)以及L-赖氨酸(4和7)的新型支链三肽。该设计策略基于这样的假设:1中的二肽半体D-Trp(CHO)-Phe-NMeBzl对于受体识别至关重要。分子模拟研究表明,这些新设计的三肽能够模拟必需二肽结构的空间取向。正如预期的那样,所有这些化合物在10(-8) M范围内均能有效抑制3H-SP(1 nM)与豚鼠肺膜的结合。如分子模拟研究所预测的,1H-吲哚-3-基羰基衍生物(5 - 7)的活性略高于相应的1H-吲哚-2-基羰基衍生物(2 - 4)。对所选1H-吲哚-3-基羰基衍生物的构效关系研究表明,侧链上的苏氨酸部分可以修饰成多种结构,而活性不会有任何显著损失。此外,在L-赖氨酸系列中,即使是在ε-氨基上没有或只有简单酰基的二肽化合物,如Nα-[Nα-(1H-吲哚-3-基羰基)-L-赖氨酰]-N-甲基-N-(苯甲基)-L-苯丙氨酰胺(18b),也表现出强效活性。这些二肽属于SP拮抗剂的一种新结构类别。